Predictive Oncology (POAI)
(Delayed Data from NSDQ)
$0.88 USD
-0.04 (-3.88%)
Updated Sep 18, 2024 04:00 PM ET
After-Market: $0.90 +0.02 (2.27%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum F VGM
Income Statements
Fiscal Year end for Predictive Oncology Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 2 | 2 | 1 | 1 | 1 |
Cost Of Goods | 1 | 1 | 0 | 0 | 1 |
Gross Profit | 1 | 1 | 1 | 1 | 1 |
Selling & Adminstrative & Depr. & Amort Expenses | 15 | 27 | 21 | 13 | 15 |
Income After Depreciation & Amortization | -14 | -26 | -20 | -12 | -14 |
Non-Operating Income | 0 | 0 | 0 | -13 | -6 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -14 | -26 | -20 | -26 | -19 |
Income Taxes | 0 | 0 | -1 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -14 | -26 | -20 | -26 | -19 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -14 | -26 | -20 | -26 | -19 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -13 | -21 | -15 | -10 | -11 |
Depreciation & Amortization (Cash Flow) | 1 | 5 | 6 | 2 | 3 |
Income After Depreciation & Amortization | -14 | -26 | -20 | -12 | -14 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 4.02 | 3.65 | 2.74 | 0.60 | 0.14 |
Diluted EPS Before Non-Recurring Items | -3.48 | -5.00 | -4.60 | -28.60 | -84.00 |
Diluted Net EPS (GAAP) | -3.48 | -7.00 | -7.20 | -44.20 | -137.20 |
Fiscal Year end for Predictive Oncology Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.28 | 0.42 | 0.34 | 0.72 | 0.49 |
Cost Of Goods | 0.15 | 0.19 | 0.25 | 0.11 | 0.16 |
Gross Profit | 0.13 | 0.23 | 0.09 | 0.61 | 0.33 |
SG&A, R&D, and Dept/Amort Expenses | 3.32 | 4.47 | 3.59 | 3.76 | 4.29 |
Income After SG&A, R&D, and Dept/Amort Expenses | -3.19 | -4.24 | -3.50 | -3.15 | -3.96 |
Non-Operating Income | 0.01 | 0.02 | 0.03 | -0.01 | 0.04 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -3.18 | -4.22 | -3.48 | -3.16 | -3.92 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -3.18 | -4.22 | -3.48 | -3.16 | -3.92 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -3.18 | -4.22 | -3.48 | -3.16 | -3.92 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 4.67 | 4.06 | 4.09 | 4.03 | 4.00 |
Diluted EPS Before Non-Recurring Items | -0.68 | -1.04 | -0.85 | -0.78 | -0.95 |
Diluted Net EPS (GAAP) | -0.68 | -1.04 | -0.86 | -0.78 | -0.98 |